Voyager Therapeutics, Inc.
For the period ended Sep 30, 2026. Filed Nov 5, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 5, 2026
VYGR$1.99+6.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
CONDENSED CONSOLIDATED BALANCE SHEETS
(amounts in thousands, except share and per share data)
| September 30, · December 31, | ||||
|---|---|---|---|---|
| 2026 · 2025 | ||||
| Assets | ||||
| Current assets: | ||||
| Cash and cash equivalents | $ | 48,408 | $ | 65,300 |
| Marketable securities | 58,398 | 131,147 | ||
| Accounts receivable | 4,017 | 1,761 | ||
| Related party collaboration receivable | 257 | 151 | ||
| Prepaid expenses and other current assets | 3,350 | 4,328 | ||
| Total current assets | 114,430 | 202,687 | ||
| Property and equipment, net | 9,767 | 13,136 | ||
| Restricted cash | 2,736 | 2,736 | ||
| Marketable securities, non-current | 25,327 | 5,244 | ||
| Other non-current assets | 214 | — | ||
| Operating lease, right-of-use assets | 24,579 | 28,478 | ||
| Total assets | $ | 177,053 | $ | 252,281 |
| Liabilities and stockholders’ equity | ||||
| Current liabilities: | ||||
| Accounts payable | $ | 1,947 | $ | 5,013 |
| Accrued expenses | 8,488 | 12,098 | ||
| Operating lease liabilities | 6,378 | 7,840 | ||
| Deferred revenue | — | 1,590 | ||
| Total current liabilities | 16,813 | 26,541 | ||
| Operating lease liabilities, net of current portion | 24,129 | 28,659 | ||
| Other non-current liabilities | 1,000 | 1,000 | ||
| Total liabilities | 41,942 | 56,200 | ||
| Commitments, contingencies, and other liabilities (see Note 7) | ||||
| Stockholders’ equity: | ||||
| Preferred stock, $0.001 par value: 5,000,000 shares authorized at September 30, 2026 and December 31, 2025; no shares issued and outstanding at September 30, 2026 and December 31, 2025 | — | — | ||
| Common stock, $0.001 par value: 240,000,000 and 120,000,000 shares authorized at September 30, 2026 and December 31, 2025, respectively; 62,173,465 and 59,047,860 shares issued and outstanding at September 30, 2026 and December 31, 2025, respectively | 62 | 59 | ||
| Additional paid-in capital | 658,687 | 641,895 | ||
| Accumulated other comprehensive (loss) income | (629) | 32 | ||
| Accumulated deficit | (523,009) | (445,905) | ||
| Total stockholders’ equity | 135,111 | 196,081 | ||
| Total liabilities and stockholders’ equity | $ | 177,053 | $ | 252,281 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.